News
2023.09.13
Felix Zhu, Vice President of GenScript ProBio, and Han Sung-jun, CTO of Dx&Vx, at the MOU signing ceremony (Courtesy of DXVX)
Dx&Vx (180400), a global contract development and manufacturing organization (CDMO), announced on September 13 that it has entered into a strategic partnership (MOU) with GenScript ProBio to develop a new antibody drug.
The signing ceremony was held at the Dx&Vx headquarters in Gasan-dong, Seoul in the presence of Han Sung-jun, Chief Technology Officer (CTO) of Dx&Vx; Kim Byung-jin, Vice President of Avixgen; and Felix Zhu, Vice President and Chief Antibody Officer at GenScript ProBio.
Dx&Vx expects this strategic partnership will yield additional pipelines.
GenScript ProBio is a global subsidiary of GenScript, a global biopharmaceutical contract research organization (CRO) and CDMO. It provides one-stop services from drug development to commercialization, with specialized solutions and efficient processes for antibody drugs and cellular and gene therapy products.
Through this strategic partnership, Dx&Vx plans to develop its own antibody drugs in full swing. Based on GenScript ProBio’s global human antibody library, the initial development phase for entry into clinical trials, from lead discovery to cell line development, chemistry, manufacturing, and controls (CMC), and nonclinical sample production, will be carried out for the new antibody drug development.
For new antibody drug development in collaboration with GenScript ProBio, the research personnel of Dx&Vx and its subsidiary Avixgen, as well as the global network of the COREE Group, will be used for the clinical study and development.
“We expect to accelerate our own drug development projects and enhance the likelihood of success by collaborating with GenScript ProBio, which has participated in the drug development projects of a number of global pharmaceutical companies,” said Dx&Vx CTO Han Sung-jun, who also added, “We will continue to expand our collaboration with global pharmaceutical and bio companies with the goal of conducting global clinical trials.”
Meanwhile, Dx&Vx has recently been working with a number of leading companies at home and abroad to secure pipelines to create value in the long run by developing new antibody drugs, in addition to the development of anticancer vaccines with Oxford Vacmedix and establishment of an eye disease treatment pipeline with Avixgen.
Source: News 1